Section Arrow
SRZN.NASDAQ
- Surrozen
Quotes are at least 15-min delayed:2024/12/23 22:19 EST
Last
 12.23
+1.665 (+15.76%)
Day High 
12.505 
Prev. Close
10.565 
1-M High
12.88 
Volume 
25.92K 
Bid
7.25
Ask
12.29
Day Low
10.35 
Open
10.35 
1-M Low
8.78 
Market Cap 
34.33M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 9.78 
20-SMA 10.12 
50-SMA 10.18 
52-W High 16.19 
52-W Low 5.9999 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-16.94/--
Enterprise Value
35.22M
Balance Sheet
Book Value Per Share
1.74
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
3.85
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TNXPTonix Pharmaceuticals Holding Corp.0.4031-0.2085-34.09%-- 
RAPTRAPT Therapeutics1.74+0.9146+110.81%-- 
TRAWTraws Pharma Inc12.57+7.55+150.40%-- 
CEROCERo Therapeutics Holdings0.0505-0.0056-9.98%-- 
RXRXRecursion Pharmaceuticals6.99+0.96+15.92%-- 
Quotes are at least 15-min delayed:2024/12/23 22:19 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.